We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




POC System Could Transform Infectious Disease Management

By LabMedica International staff writers
Posted on 27 May 2022
Print article
Image: SAMBA II is a real game changer in infectious disease management (Photo courtesy of DRW)
Image: SAMBA II is a real game changer in infectious disease management (Photo courtesy of DRW)

A new platform supports rapid, efficient and accurate diagnosis of multiple infectious diseases, aiding clinical decision-making, and enabling improved, timely access to healthcare for all.

DRW’s (Diagnostics for the Real World, Cambridge, UK) SAMBA II is a robust, simple-to-use system offers a complete end-to-end process, delivering fast results and reducing the typical 1-2 day wait from centralized laboratory tests. The SAMBA II system delivers a true point-of-care system, from sample extraction, through to isothermal nucleic acid amplification, patented lateral flow detection and automated interpretation of results.

SAMBA II is a real game changer in infectious disease management. It is fully automated, performing sample preparation, extraction, amplification and detection: a true sample in – result out system. With SAMBA II, high-tech diagnostic and treatment monitoring assays become easy to perform and require minimal training. While-you-wait results enable test and treat facilities, enhancing the way diseases are managed. Safe and easy to use, the uniquely shaped ready-to use cartridges are easy to load and include all consumables. The visual results are automatically analyzed by the integrated camera to ensure consistent and accurate interpretation, with results presented and stored on the connected tablet. SAMBA II delivers innovative assays in an easy-to-use and accessible platform for the diagnosis and treatment monitoring of infectious disease at the point of care, including HIV, SARS-CoV-2, hepatitis B and C, and influenza A and B.

The SAMBA II system is comprised of the assay module, where the test is performed, and the tablet module, which controls the assay module and displays the test results. Each tablet module can control up to four assay modules, allowing flexibility and scalability at sites using SAMBA II. SAMBA II is a connected platform. The tablet module controls the assay module and receives all results via Bluetooth. The tablet module can send results to the Bluetooth printer, or via SMS, mobile Internet or Wi-Fi to a backup tablet or a tablet in a remote clinic who send their samples to be tested with SAMBA II. The tablet module can also send test results in a standard format to a laboratory information system (LIS), to a Ministry of Health service or to the SAMBA dashboard. Test results can also be downloaded directly from the tablet via USB. With SAMBA II, test results can be sent to those that need them.

Related Links:
DRW 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.